Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | TYMP | P19971 | 8/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 2/20 | 0.39 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19127764 | 1.00 | ADORA1 (0.49) | ADORA1TYMPNT5EP2RY12NNMT | |
| SCHEMBL19127240 | 0.88 | TYMP (0.45) | ADORA1TYMPNT5ENNMT | |
| SCHEMBL19127241 | 0.87 | TYMP (0.46) | ADORA1TYMPP2RY12 | |
| SCHEMBL19127992 | 0.86 | TYMP (0.52) | TYMPNT5E | |
| SCHEMBL19127991 | 0.86 | TYMP (0.52) | TYMPNT5E | |
| SCHEMBL7210212 | 0.85 | ADORA1 (0.52) | ADORA1TYMPNT5ETRDMT1CARM1 | |
| SCHEMBL28827070 | 0.84 | ADORA1 (0.51) | ADORA1TYMPNT5ETRDMT1CARM1 | |
| SCHEMBL19145869 | 0.84 | ADORA3 (0.50) | ADORA1P2RY12 | |
| SCHEMBL20637781 | 0.83 | ADORA1 (0.50) | ADORA1TYMPNT5ETRDMT1CARM1 | |
| SCHEMBL19927404 | 0.81 | AHCY (0.53) | ADORA1NT5EP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402801-B1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | INNATE TUMOR IMMUNITY INC (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-109451740-B | Cyclic dinucleotides for the treatment of disorders associated with STING activity, such as cancer | 先天肿瘤免疫公司 | 2022-09-02 | — | — | CN | disclosed |